Pharmaceuticals company Solara Active Pharma Sciences announced Q2FY27 results Consolidated Financial Highlights: Total Income: Rs 417.88 crore (up from Rs 314.03 crore in Q2FY26). Net Profit for the Period: Rs 28.46 crore (up from Rs -10.10 crore in Q2FY26). Total Comprehensive Income: Rs 28.59 crore (up from Rs -9.29 crore in Q2FY26). Earnings Per Share (Basic): Rs 5.92 (up from Rs -2.36 in Q2FY26). Financial Position & Solvency: Total Assets (Consolidated): Rs 2,454.13 crore as of September 30, 2026, compared to Rs 2,332.59 crore as of March 31, 2026. Accumulated Losses: As of September 30, 2026, the company has accumulated losses of Rs 274.16 crore. Despite this, management has prepared the results on a "going concern" basis, citing improved business performance, anticipated growth, and adequate resources to meet obligations. Cash Flow: The group generated Rs 63.35 crore in net cash from operating activities during H1 2026. Business Highlights: Rights Issue: The company successfully raised Rs 446.62 crore (out of a total issue size of Rs 449.95 crore) through a rights issue offered in May 2024. The final call for these shares was made in May 2026. Proposed Demerger: The Board has given in-principle approval to explore the demerger of its CRAMS (Contract Research and Manufacturing Services) and Polymers business into a separate independent listed entity. A new subsidiary, Synthix Global Pharma Solutions Limited, was incorporated in April 2025 for this purpose. Exceptional Item: The company recorded an exceptional loss of Rs 4.50 crore during the current quarter due to the sale of Capital Work in Progress (CWIP) at its mothballed Vizag plant. Subsidiary Closure: The company completed the closure of its Brazilian subsidiary, Solara Active Pharma Sciences LTDA, with its registration cancelled effective September 16, 2025. Auditor Review: Statutory auditors Deloitte Haskins & Sells LLP conducted a limited review of the results and issued an unmodified conclusion for both standalone and consolidated statements. Sandeep Rao, Managing Director & CEO, said: Our Base business continues to lead our growth. Revenue grew 37% to Rs 3,273 million, staying above Rs 3,000 million for the third quarter in a row, and EBITDA grew 68% to Rs 771 million, with the margin up about 440 bps to 23.6% even as raw material costs rose. Ibuprofen is turning around. Revenue grew 21% over last year and 18% over last quarter, and the business is now close to breakeven, from a loss margin of 21% just two quarters ago. As a result, overall revenue grew 33% to Rs 4,178 million and EBITDA more than doubled, up 118% to Rs 769 million. We are firmly back in profit, with PAT of Rs 285 million against a loss of Rs 101 million a year ago. Net debt to EBITDA is down to about 1.8x from 3.2x at the end of FY26, giving us room to keep investing in growth Result PDF